3 -Azido-3 -deoxythymidine , 5’monophosphate

ADP adenosine diphosphate, ANP atrial natriuretic peptide, AP5DTPT(5 -adenosyl)P5-(5 -thymidyl)pentaphosphate, ATP adenosine triphosphate, AZTMP 3 -azido-3 -deoxythymidine monophosphate, dGMP deoxyguanosine monophosphate, P 4-(2-hydroxyethyl)-l-piperazine ethanesulfonic acid, HMD hymenialdisine, TMP thymidine monophosphate... 

The constrained nucleosides are of interest as leads for small-molecule therapeutics. For example, the (3-2 -0,3 -C-oxetane analogues of the antiviral 3 -azido-3 -deoxythymidine (AZT), which exist predominantly in the E-like conformation (see, for example, Equation 55), were investigated for inhibition of human immunodeficiency virus 1 (HIV-1). Neither the modified nucleosides nor their 5 -monophosphate analogues inhibit HIV-1, supporting a hypothesis that reverse transcriptase inhibitors must have conformational freedom <2001JOC4878, 2002J(P1)1655>. 

Nucleoside analogues are widely used as antiviral agents in the treatment in AIDS and AIDS-related complex. The only clinical agent approved in the United States for the treatment of AIDS is 3 -azido-3 -deoxythymidine (AZT) [54,55]. The molecular mechanism of action for this nucleoside includes conversion into its corresponding 5 -monophosphate by the action of cellular nucleoside kinase, followed by stepwise phosphorylation catalyzed by cellular nucleoside kinase to the corresponding 5 -triphosphate. These inhibit proviral DNA synthesis [55-57], catalyzed by HIV reverse transcriptase (RT), and incorporation to the 3 end of the growing DNA chain [55,58]. 

---